Patents by Inventor George M. Shaw
George M. Shaw has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240123050Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.Type: ApplicationFiled: May 1, 2023Publication date: April 18, 2024Inventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
-
Patent number: 11660332Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.Type: GrantFiled: April 27, 2018Date of Patent: May 30, 2023Assignees: The Trustees of the University of Pennsylvania, The Johns Hopkins University, Vanderbilt UniveisilyInventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
-
Patent number: 10946090Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.Type: GrantFiled: November 15, 2017Date of Patent: March 16, 2021Assignees: Duke University, The University of Alabama at Birmingham Research Foundation, Triad National Security, LLCInventors: Barton F. Haynes, Feng Gao, Bette T. Korber, Beatrice H. Hahn, George M. Shaw, Denise L. Monti, Ying Ying Li, Julie Decker, Hua-Xin Liao
-
Patent number: 10849970Abstract: The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).Type: GrantFiled: January 8, 2018Date of Patent: December 1, 2020Assignees: Duke University, Triad National Security, LLC, The Trustees of The University of Pennsylvania, Trustees of Boston University, The Government of The United States of America as Represented by the Secretary of the Department of Health and Human Services, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Barton F. Haynes, Hua-Xin Liao, Rebecca M. Lynch, Tongqing Zhou, Feng Gao, Scott Boyd, George M. Shaw, Beatrice H. Hahn, Thomas B. Kepler, Bette T. Korber, Peter Kwong, John R. Mascola
-
Publication number: 20200222528Abstract: The present invention relates to compositions and methods for inducing an adaptive immune response against Hepatitis C virus (HCV) in a subject. In some embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof. For example, in some embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a HCV antigen, adjuvant, or a combination thereof.Type: ApplicationFiled: April 27, 2018Publication date: July 16, 2020Inventors: Drew Weissman, George M. Shaw, Justin R. Bailey, Stuart C. Ray, James Crowe, Jr., Andrew Flyak
-
Patent number: 10561725Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.Type: GrantFiled: December 13, 2013Date of Patent: February 18, 2020Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Barton F. Haynes, Hua-Xin Liao, Li-Hua Ping, Ronald Swanstrom, Beatrice H. Hahn, George M. Shaw
-
Patent number: 10322141Abstract: In certain aspects the invention provides immunogenic compositions comprising CH848 HIV-1 envelopes and their use in methods to induce immune responses in subjects, e.g., human subjects.Type: GrantFiled: March 31, 2015Date of Patent: June 18, 2019Assignees: DUKE UNIVERSITY, TRIAD NATIONAL SECURITY, LLC, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Barton F. Haynes, Beatrice H. Hahn, George M. Shaw, Bette T. Korber, Peter T. Hraber
-
Publication number: 20180360948Abstract: The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).Type: ApplicationFiled: January 8, 2018Publication date: December 20, 2018Inventors: Barton F. HAYNES, Hua-Xin LIAO, Rebecca M. LYNCH, Tongqing ZHOU, Feng GAO, Scott BOYD, George M. SHAW, Beatrice H. HAHN, Thomas B. KEPLER, Bette T. KORBER, Peter KWONG, John R. MASCOLA
-
Publication number: 20180296665Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.Type: ApplicationFiled: November 15, 2017Publication date: October 18, 2018Inventors: Barton F. Haynes, Feng Gao, Bette T. Korber, Beatrice H. Hahn, George M. Shaw, Denise Kothe, Ying Ying Li, Julie Decker, Hua-Xin Liao
-
Patent number: 10004800Abstract: The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).Type: GrantFiled: September 12, 2013Date of Patent: June 26, 2018Assignees: Duke University, Los Alamos National Security, LLC, The Trustees of The University of Pennsylvania, Trustees of Boston University, The United States of America as Represented by The Secretary of the Department of Health and Human Services National Institutes of Health Office of Technology Transfer, The Board of Trustees of the Leland Stanford Junior UniversityInventors: Barton F. Haynes, Hua-Xin Liao, Rebecca M. Lynch, Tongqing Zhou, Feng Gao, Scott Boyd, George M. Shaw, Beatrice H. Hahn, Thomas B. Kepler, Bette T. Korber, Peter Kwong, John Mascola
-
Patent number: 9844589Abstract: The invention relates to HIV-1 envelope polypeptides comprising the consensus envelope of SEQ ID NO: 35, compositions comprising these envelopes and methods for using same.Type: GrantFiled: August 23, 2011Date of Patent: December 19, 2017Assignees: DUKE UNIVERSITY, THE UNIVERSITY OF ALABAMA BIRMINGHAM RESEARCH FOUNDATION, LOS ALAMOS NATIONAL SECURITY, LLCInventors: Barton F. Haynes, Feng Gao, Bette T. Korber, Beatrice H. Hahn, George M. Shaw, Denise Kothe, Ying Ying Li, Julie Decker, Hua-Xin Liao
-
Publication number: 20170312303Abstract: In certain aspects the invention provides immonogenic compositions comprising CH848 HIV-1 envelopes and their use in methods to induce immune responses in subjects, e.g., human subjects.Type: ApplicationFiled: March 31, 2015Publication date: November 2, 2017Inventors: Barton F. HAYNES, Beatrice H. HAHN, George M. SHAW, Bette T. KORBER, Peter T. HRABER
-
Patent number: 9309574Abstract: Disclosed is the molecular cloning of HTLV-III, the adult leukemia and acquired immune deficiency syndrome (AIDS) virus. Clone BH10 contains a 9.0 Kb viral insert constituting the entire HTLV-III genome. Clones BH8 and BH5 contain viral inserts of 5.5 Kb and 3.5 Kb, respectively. These clones are suitable for the development of diagnostic and therapeutic measures for AIDS, as well as use as probes for the detection of AIDS. By scientific convention, HTLV-III, referred to herein also as HIV, has been renamed as HIV-1.Type: GrantFiled: February 8, 1995Date of Patent: April 12, 2016Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServicesInventors: Robert C. Gallo, Flossie Wong-Staal, Mikulas Popovic, Beatrice H. Hahn, George M. Shaw, Amanda G. Fisher
-
Publication number: 20150366961Abstract: The present invention relates, in general, to HIV-1 and, in particular, to broadly neutralizing HIV-1 antibodies, and to HIV-1 immunogens and to methods of using such immunogens to induce the production of broadly neutralizing HIV-1 antibodies in a subject (e.g., a human).Type: ApplicationFiled: September 12, 2013Publication date: December 24, 2015Inventors: Barton F. HAYNES, Hua-Xin LIAO, Rebecca M. LYNCH, Tongqing ZHOU, Feng GAO, Scott BOYD, George M. SHAW, Beatrice H. HAHN, Thomas B. KEPLER, Bette T. KORBER, Peter KWONG, John MASCOLA
-
Publication number: 20140248301Abstract: The present invention relates, in general, to an immunogen for HIV vaccination and, in particular, to a method of inducing the production of protective anti-HIV antibodies by targeting B cell germline and clone intermediates using a combination of HIV envelope and non-HIV immunogens. The invention also relates to compositions suitable for use in such a method.Type: ApplicationFiled: December 13, 2013Publication date: September 4, 2014Inventors: Barton F. Haynes, Hua-Xin Liao, Li-Hua Ping, Ronald Swanstrom, Beatrice H. Hahn, George M. Shaw
-
Patent number: 8647818Abstract: Methods and compositions are provided which employ chimeric polypeptides having at least one heterologous epitope for a human immunodeficiency virus type 1 (HIV-1) neutralizing antibody. These chimeric polypeptides behave as molecular scaffolds which are capable of presenting the various heterologous HIV-1 epitopes. The invention demonstrates that a heterologous epitope recognized by the HIV-1 neutralizing antibody can be more fully exposed to neutralizing antibodies when presented within the backbone of the chimeric polypeptide than when the epitope is presented within the context of an HIV-1 backbone. Polynucleotides encoding these chimeric polypeptides are also provided. Immunogenic compositions are provided which comprise a chimeric polypeptide having at least one heterologous epitope that interacts with an HIV-1 neutralizing antibody. Immuno genie compositions comprising chimeric polynucleotides encoding the chimeric polypeptides of the invention are also provided.Type: GrantFiled: February 16, 2006Date of Patent: February 11, 2014Assignees: UAB Research Foundation, University of Alabama—Birmingham, The United States of America, as represented by the Secretary, Department of Health and Human Services (Hereinafter the Government) Office of Technology Transfer, National Institutes of HealthInventors: George M. Shaw, Beatrice H. Hahn, Frederic Bibollet-Ruche, Peter D. Kwong
-
Patent number: 8637234Abstract: Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.Type: GrantFiled: April 8, 2005Date of Patent: January 28, 2014Assignees: UAB Research Foundation, The Administrators of Tulane Educational Fund, The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: George M. Shaw, James E. Robinson, Frederic Bibollet-Ruche, Julie M. Decker, Beatrice H. Hahn, Peter D. Kwong
-
Publication number: 20140023683Abstract: This invention provides methods for identifying HCV genomes and more specifically, methods for identifying nucleotide sequence of viral structural proteins at the time of HCV viral transmission. The method of the invention utilizes single genome amplification and sequencing of circulating virus as well as phylogenetic analysis of the resulting nucleotide sequence for identifying transmitted HCV genomes. Also provided are HCV genomes and corresponding nucleotide sequence for transmitted and circulating HCV virus. The invention further provides methods of administering a vaccine comprising one or more identified transmitted HCV sequences.Type: ApplicationFiled: September 8, 2011Publication date: January 23, 2014Applicants: THE UAB RESEARCH FOUNDATION, DUKE UNIVERSITYInventors: George M. Shaw, Hui Li, Beatrice H. Hahn, Barton F. Haynes
-
Publication number: 20130177583Abstract: The present invention relates, in general, to HIV-1 and, in particular, to a molecular clone of HIV-1. The invention further relates to methods of inducing an immune response to HIV-1 in a patient and to immunogens suitable for use in such methods. The invention also relates to anti-HIV-1 antibodies and to methods of using same to prevent or treat HIV-infection.Type: ApplicationFiled: March 3, 2011Publication date: July 11, 2013Applicants: Duke University, The UAB Research FoundationInventors: George M. Shaw, Beatrice H. Hahn, Hui Li, Barton F. Haynes, Martin Markowitz
-
Publication number: 20120087938Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.Type: ApplicationFiled: August 23, 2011Publication date: April 12, 2012Applicants: DUKE UNIVERSITY, THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION, THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Barton F. Haynes, Feng Gao, Bette T. Korber, Beatrice H. Hahn, George M. Shaw, Denise Kothe, Ying Ying Li, Julie Decker, Hua-Xin Liao